International Cancer Patient Coalition

United Kingdom



Colorectal Cancer Factsheet: Insights & Key Developments

Key Insights on Colorectal Cancer Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Colorectal Cancer Screening

Colorectal cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping colorectal cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- Incidence share: Colorectal cancer is the third most common cancer in men.
- Incidence rate: Around 50 per 100,000 men per year.
- Total new cases (2022): Approximately 22,000 men.
- Daily diagnoses (2022): Around 60 men per day.
- Deaths (2022): About 8,400 men.
- 5-year survival rate: Estimated 65–70%.
- Most affected age group: Men aged 60–79.
- Screening participation: National screening program using FIT/colonoscopy; high participation among age 60+.

International Cancer Patient Coalition

United Kingdom

Infrastructure



Strengths

- The NHS provides universal access to diagnostic and cancer treatment services, with over 160 endoscopy units across the UK.
- Specialist Bowel Cancer Screening Centres and Cancer Hubs provide streamlined care pathways.

Weakness

- Delays in colonoscopy access persist post-COVID, with some areas having wait times over 6 weeks.
- Regional disparity in diagnostic capacity between rural areas and major NHS trusts.

S W O T

Opportunity

- Investment in digital pathology and AI-driven tools to improve efficiency in diagnosis.
- Modernization programs for diagnostic centers under NHS England's elective recovery plan.

Threats

- Staffing shortages, especially endoscopy nurses and radiologists, threaten service continuity.
- Strained hospital infrastructure due to increased cancer incidence and aging population.

5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.

4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.

3. Moderate infrastructure, primarily in private settings or research institutions.

2. Limited infrastructure, available only in select centers or for high-cost private testing.

1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	3	3
Kenya	2	2
Nigeria	2	2
Egypt	2	3
Morocco	2	2
Algeria	2	2
Ethiopia	1	1
India	3	4
Japan	4	4
South Korea	4	4
China	4	4
Thailand	3	3
Singapore	4	4
United Kingdom	4	4
Germany	5	4
France	4	4
Netherlands	5	4
Sweden	5	4
Italy	4	4
Spain	4	4
Poland	4	3
Mexico	2	3
Brazil	3	3
Argentina	3	3
Chile	3	3
Colombia	2	3
United States	5	5
Canada	5	4
Australia	4	4
New Zealand	4	4
Greece	4	3
Rwanda	1	1
Uganda	1	1
Serbia	3	3
Saudi Arabia	4	4
UAE	4	4
Syria	1	1
Indonesia	2	2
Vietnam	3	3
Philippines	2	2
Russia	4	3
Malaysia	4	4

International Cancer Patient Coalition

United Kingdom

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Wide access to chemotherapy, surgery, radiotherapy, and targeted therapies under NHS.
- The UK is a global leader in CRC research, with institutions like Cancer Research UK and NIHR funding major trials.

Weakness

- Certain innovative drugs have slow adoption due to NICE cost-effectiveness reviews.
- Low participation in screening among lower-income groups and minorities despite outreach.

S W O T

Opportunity

- Leverage celebrity-endorsed awareness campaigns like “Be Clear on Cancer” to boost participation.
- Expand clinical trial access through decentralised recruitment and digital platforms.

Threats

- Budget constraints and changing political priorities may reduce future research funding.
- Brexit-related research collaboration limitations may reduce cross-EU CRC studies.

5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.

4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.

3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.

2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.

1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	3	3	3
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	5
South Korea	4	4	5
China	3	3	3
Thailand	2	3	2
Singapore	4	5	5
United Kingdom	4	5	5
Germany	5	5	5
France	4	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	3	3
Brazil	2	3	3
Argentina	2	3	3
Chile	2	3	3
Colombia	1	2	2
United States	5	5	5
Canada	5	5	5
Australia	4	4	4
New Zealand	3	3	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	3
Saudi Arabia	3	2	3
UAE	4	3	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	1	2
Philippines	3	2	2
Russia	3	3	2
Malaysia	3	3	3

International Cancer Patient Coalition

United Kingdom

Survival Rates, Early Detection and Palliative Care



Strengths

- 5-year survival rates for Stage I CRC are above 90%; overall survival has steadily improved.
- Hospice and palliative care services are well-integrated, with high opioid access and home-based care support

Weakness

- 20% of CRC cases still diagnosed at emergency presentation, with significantly lower survival.
- Socioeconomic disparities lead to unequal outcomes across patient groups.

S W O T

Opportunity

- Incorporate personalized risk-based screening to catch high-risk cases earlier.
- Further integrate primary care into early detection pathways for CRC.

Threats

- Rising burden of CRC in younger populations may outpace current early detection models.
- Long-term impact of COVID-related diagnostic backlogs still unfolding.

5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.

4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.

3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.

2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.

1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	2	3	2
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	5	4	5
South Korea	5	4	5
China	3	3	4
Thailand	2	2	2
Singapore	5	5	5
United Kingdom	5	5	5
Germany	5	5	5
France	5	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	5	4	5
Spain	5	4	5
Poland	3	3	4
Mexico	2	2	2
Brazil	3	3	3
Argentina	3	3	3
Chile	3	3	3
Colombia	2	2	2
United States	5	5	5
Canada	5	5	5
Australia	5	4	4
New Zealand	4	4	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	2
Saudi Arabia	3	2	3
UAE	4	3	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	1	2
Philippines	2	3	2
Russia	4	3	3
Malaysia	3	2	3

International Cancer Patient Coalition

United Kingdom

Utilization of Biomarkers



Strengths

- NHS Genomic Medicine Service enables routine KRAS, NRAS, BRAF, MSI, and dMMR testing for CRC patients.
- NICE guidelines incorporate biomarker use in therapy decision-making (e.g., anti-EGFR for RAS wild-type).

Weakness

- Delays in biomarker result turnaround in some secondary hospitals affect timely treatment planning.
- Limited awareness among GPs and non-specialist oncologists regarding evolving biomarker implications

S W O T

Opportunity

- Expansion of whole genome sequencing via Genomics England for complex CRC cases.
- Broader biomarker panel testing could support eligibility for new immunotherapies.

Threats

- Variability in implementation of molecular diagnostics across NHS Trusts.
- Costs of next-gen sequencing and infrastructure scaling may delay full adoption.

Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.

Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.

Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



International Cancer Patient Coalition

United Kingdom

Clinical Guidelines



Strengths

- NICE and NHS provide comprehensive, regularly updated CRC guidelines based on latest evidence.
- Clear stratification by stage and molecular profile supports personalized care.

Weakness

- Guideline updates sometimes lag behind rapid global clinical advances (e.g., new biomarker-driven trials).
- Implementation consistency across local NHS Trusts varies.

Opportunity

- Use real-world evidence (RWE) from NHS datasets to refine guidelines dynamically.
- Introduce AI-powered clinical decision support systems integrated with EHRs.

Threats

- Bureaucratic delays in updating or approving new guideline pathways can hinder innovation uptake.

	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	O	✖	✖	✖	✖
Feasibility of Integration	O	✖	✖	✖	✖
Adoption of International Guidelines	O	✖	✖	✖	✖
Engagement with Updates	✖	O	✖	✖	✖
ESMO Guidelines Implementation	O	✖	✖	✖	✖

International Cancer Patient Coalition

United Kingdom

Reimbursement

Strengths

- NHS offers full reimbursement for most standard CRC treatments, including surgery, chemotherapy, and radiotherapy.
- NICE processes ensure drug cost-effectiveness and equity.

Weakness

- New biomarker-driven or immunotherapy drugs may be denied or delayed due to high cost per QALY thresholds.
- Coverage gaps for supportive treatments, especially for advanced-stage patients.

S W O T

Opportunity

- Expansion of the Cancer Drugs Fund provides temporary access while drugs undergo full NICE review.
- Flexible pricing negotiations with pharma can enable faster patient access.

Threats

- Post-Brexit changes in pharmaceutical pricing policies could impact future reimbursement decisions.
- Economic constraints may restrict future cancer funding allocations.

● A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.

● A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.

● No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement Framework	No-cost Access
United States	●	○
United Kingdom	●	●
Canada	●	●
Australia	●	●
Germany	●	●
France	●	●
Netherlands	●	●
Sweden	●	●
Italy	●	●
Spain	●	●
Poland	●	●
Japan	●	●
South Korea	●	●
China	●	●
India	○	○
Singapore	●	●
Thailand	●	●
South Africa	○	○
Kenya	○	○
Nigeria	○	○
Egypt	○	○
Morocco	○	○
Algeria	●	●
Ethiopia	○	○
Mexico	●	●
Brazil	●	●
Argentina	●	●
Chile	●	●
Colombia	●	●
New Zealand	●	●
Greece	●	●
Rwanda	○	○
Uganda	○	○
Serbia	●	●
Saudi Arabia	●	●
UAE	●	●
Syria	○	○
Indonesia	●	○
Vietnam	●	○
Philippines	○	○
Russia	●	●
Malaysia	●	●

International Cancer Patient Coalition

United Kingdom

Colorectal Cancer Screening

Strengths

- National Bowel Cancer Screening Programme (BCSP) offers biennial FIT kits to adults aged 56–74.
- FIT uptake is high in some regions, with early detection rates improving consistently.

Weakness

- Uptake still below 65% in many deprived areas; lower participation among South Asian and Black communities.
- Screening age remains a barrier—cases in younger adults often missed.



Opportunity

- Planned lowering of screening start age to 50 could significantly improve early detection.
- Community pharmacy and primary care-led FIT distribution can improve access.

Threats

- NHS backlog in colonoscopy capacity may delay follow-up for FIT-positive patients.
- Public misinformation and stigma around colonoscopy may reduce participation.

Country	Colorectal Cancer Screening
United States	Annual LDCT (50-80 years, high-risk smokers)
United Kingdom	LDCT for high-risk individuals (55-74 years)
Canada	LDCT for high-risk individuals (55-74 years)
Australia	No national program, high-risk groups advised LDCT
Germany	No national program, under evaluation
France	No national LDCT screening
Netherlands	Participating in European screening studies
Sweden	No national LDCT screening
Italy	Regional pilot LDCT screening
Spain	No national LDCT program
Poland	No national program
Japan	No national LDCT program
South Korea	LDCT for high-risk individuals (50-74 years)
China	No national LDCT program
India	No national LDCT program
Singapore	No national LDCT program
Saudi Arabia	No national LDCT program; some hospital-based opportunistic screening
UAE	No national LDCT program; early-stage pilot studies ongoing in select hospitals
Syria	No national LDCT program; screening not prioritized due to conflict
Malaysia	No program; high-risk CT pilots

Country	Colorectal Cancer Screening
Thailand	No national LDCT program
South Africa	No national LDCT program
Kenya	No national LDCT program
Nigeria	No national LDCT program
Egypt	No national LDCT program
Morocco	No national LDCT program
Algeria	No national LDCT program
Ethiopia	No national LDCT program
Mexico	No national LDCT program
Brazil	No national LDCT program
Argentina	No national LDCT program
Chile	No national LDCT program
Colombia	No national LDCT program
New Zealand	No national LDCT program
Greece	No national LDCT program
Rwanda	No national LDCT program
Uganda	No national LDCT program
Serbia	No national LDCT program
Indonesia	No national LDCT program; opportunistic screening in private sector
Vietnam	No national LDCT program; early pilot screening studies in Hanoi and Ho Chi Minh
Philippines	No national LDCT program; feasibility and awareness programs under discussion
Russia	No formal national LDCT program; regional pilot screening programs in large cities